Starving leukemia cells of the nutrients they need to survive is a real and active area of cancer medicine, not just a metaphor. But it works through targeted medical therapies that exploit specific metabolic weaknesses in leukemia cells, not through dietary changes like fasting or cutting out sugar. Several treatments already in clinical use do exactly this: they block the fuels leukemia depends on while leaving healthy cells largely unharmed.
What Leukemia Cells Are Hungry For
Leukemia cells burn through nutrients at an abnormal rate. They consume far more glucose than healthy cells, a pattern first identified nearly a century ago and now well established across multiple leukemia types. In acute lymphoblastic leukemia (ALL), the genes that drive glucose processing are cranked up while the genes for normal energy production are dialed down. The cells become dependent on this fast, inefficient way of burning sugar.
But glucose is only part of the picture. Acute myeloid leukemia (AML) cells are especially dependent on glutamine, an amino acid. When glutamine is removed from AML cells in the lab, they die. Glutamine fuels the energy-producing machinery inside these cells, and without it, that machinery shuts down. T-cell ALL also relies heavily on glutamine to sustain growth.
Fat is the third major fuel. AML cells depend on breaking down fatty acids for energy, and bone marrow fat cells actively feed leukemia by supplying those fatty acids. Some AML cells are so locked into burning fat that blocking the transport of fatty acids into their energy centers causes the cells to stop growing and self-destruct.
Leukemia cells also play dirty. AML can raise levels of a protein that makes healthy tissues resistant to insulin, effectively reducing how much glucose normal cells absorb. Since leukemia cells don’t need insulin to take in glucose, this gives them a competitive advantage: they hog the fuel supply while the rest of the body gets less.
Treatments That Already “Starve” Leukemia
Cutting Off Asparagine
The oldest and most proven example of starving leukemia is a drug called L-asparaginase, a cornerstone of ALL treatment for decades. It works on a simple principle: ALL cells cannot make their own asparagine, an amino acid essential for building proteins. Healthy cells can produce it internally, but leukemia cells depend entirely on what’s circulating in the blood. L-asparaginase breaks down asparagine in the bloodstream, eliminating the supply. Without it, the leukemia cells can’t build proteins and die. This drug, originally developed for children, is now used in adult ALL treatment as well, where pediatric-inspired regimens incorporating it have improved outcomes.
Blocking a Broken Enzyme
Some AML cells carry mutations in enzymes called IDH1 or IDH2 that normally help process nutrients inside cells. When mutated, these enzymes produce a toxic byproduct that jams the cell’s ability to mature, keeping it locked in a rapidly dividing, immature state. Drugs like ivosidenib (for IDH1 mutations) and enasidenib (for IDH2 mutations) block this broken enzyme, eliminating the toxic byproduct and allowing leukemia cells to mature and eventually die. These are now part of standard treatment guidelines. In clinical trials, ivosidenib combined with another drug showed clear superiority over standard therapy alone for IDH1-mutant AML, producing true complete remissions. Some patients in remission remained on treatment for over a year. The 2025 NCCN guidelines emphasize genetic testing at diagnosis and relapse specifically to identify these targetable mutations.
Shutting Down the Energy Factory
Leukemia stem cells, the deep-rooted cells that can regenerate the disease after treatment, rely on a specific energy production process inside their mitochondria. A drug called venetoclax suppresses this process, effectively cutting the power supply to these stem cells. When combined with other agents that further disrupt the cell’s energy cycle, the effect is amplified. Lab studies show this combination reduces the activity of key energy-producing pathways before the cells even begin to die, confirming the cells are being starved of energy rather than simply poisoned.
Experimental Approaches in Development
Glutamine Blockers
Because AML and some ALL cells are so dependent on glutamine, researchers have developed drugs that block the enzyme responsible for processing it. One such compound, CB-839, reduced glutamine processing inside AML cells and suppressed growth by more than 40% across all cell lines tested. In leukemia cells with IDH1 or IDH2 mutations, CB-839 also cut production of the same toxic byproduct targeted by ivosidenib and enasidenib, pushing the cells to mature and die. Glutamine-blocking drugs are being evaluated in clinical trials both alone and in combination with other therapies.
Blocking Sugar Processing
AML cells depend on a specific enzyme to keep their sugar-burning cycle running. This enzyme converts one molecule into another while recycling a helper molecule called NAD+ that the whole process needs to continue. When researchers blocked this enzyme in lab studies, sugar processing dropped within minutes. Levels of sugar-related molecules inside the cells fell significantly within 15 minutes, and the cells couldn’t compensate using other pathways. This confirms AML cells are critically dependent on this single step in their sugar metabolism, making it a potential drug target.
Triggering Iron Overload
A newer approach exploits leukemia cells’ relationship with iron. Leukemia cells often have high levels of iron-importing proteins on their surface and low levels of the only protein that pumps iron out. This combination traps iron inside the cell. Researchers are exploring ways to push this imbalance further, flooding leukemia cells with iron to trigger a form of cell death called ferroptosis, where excess iron drives a chain reaction of damage to the cell’s outer membranes. In lab studies, compounds that break down the cell’s iron storage proteins or boost iron uptake have successfully triggered this process in AML cells. Iron-based cell death can be blocked by iron-removing agents, confirming the mechanism is truly iron-dependent.
Why Fasting or Dietary Changes Won’t Work
Given that leukemia cells are hungry for glucose, glutamine, and fat, it’s natural to wonder whether you could starve them by changing what you eat. The short answer is no, and attempting it could be dangerous. Your body tightly regulates blood sugar and amino acid levels regardless of what you eat. You cannot selectively deprive leukemia cells of glucose through diet because your liver will produce glucose from other sources to maintain blood levels. And as noted above, AML cells can actually manipulate your body’s insulin system to redirect glucose toward themselves and away from healthy tissues.
Fasting during leukemia treatment carries specific risks. Cancer patients frequently experience severe muscle loss and fat depletion, a condition called cachexia. Fasting can accelerate this process, weakening immune function, reducing the body’s ability to tolerate chemotherapy, and worsening overall prognosis. Many oncologists are cautious about fasting for cancer patients even in controlled settings. There is currently insufficient evidence to support fasting as a treatment for any cancer, and for leukemia patients who are often already immunocompromised and losing weight, the risks are particularly high.
The medical therapies described above succeed precisely because they target molecular vulnerabilities specific to leukemia cells. L-asparaginase works because healthy cells make their own asparagine and leukemia cells cannot. IDH inhibitors work because only mutant cells produce the toxic byproduct. These are precision tools, not blunt instruments. A dietary approach cannot replicate this specificity.
How Metabolic Targeting Fits Into Treatment
Metabolic therapies are not standalone cures. They work alongside or as part of broader treatment plans. L-asparaginase is given as part of multi-drug chemotherapy regimens. IDH inhibitors are typically combined with other agents like azacitidine. Venetoclax is paired with drugs that attack different vulnerabilities simultaneously. The goal in each case is to cut off the leukemia’s energy supply while other treatments deliver additional damage the cells can’t recover from.
The effectiveness of these approaches depends heavily on genetic testing. The 2025 treatment guidelines stress comprehensive mutation profiling at both diagnosis and relapse, because the specific mutations present in your leukemia determine which metabolic vulnerabilities can be targeted. A patient with an IDH1 mutation has a clear path to a well-tolerated oral medication that produces genuine remissions. A patient without that mutation needs a different strategy. This is why molecular profiling has become the foundation of modern leukemia treatment: it identifies which fuel lines can be cut for each individual patient.
For elderly patients, who historically had overall survival under one year with standard chemotherapy, metabolic-targeting drugs have been especially meaningful. Many of these medications are oral, better tolerated than traditional chemotherapy, and can keep the disease stable even when full remission isn’t achieved. They represent a shift from trying to poison cancer cells faster than healthy ones, toward identifying what makes leukemia cells uniquely vulnerable and exploiting that difference.